vs
Orthofix Medical Inc.（OFIX）与TOOTSIE ROLL INDUSTRIES INC（TR）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是TOOTSIE ROLL INDUSTRIES INC的1.1倍（$219.9M vs $196.3M），TOOTSIE ROLL INDUSTRIES INC净利率更高（14.7% vs -1.0%，领先15.7%），Orthofix Medical Inc.同比增速更快（2.0% vs 1.5%），TOOTSIE ROLL INDUSTRIES INC自由现金流更多（$61.0M vs $16.8M），过去两年TOOTSIE ROLL INDUSTRIES INC的营收复合增速更高（13.2% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
图西罗工业是总部位于美国伊利诺伊州芝加哥的糖果生产企业，核心产品包括同名的图西罗软糖、图西棒棒糖等广受欢迎的糖果产品，旗下品牌目前已销往加拿大、墨西哥等全球超过75个国家和地区。
OFIX vs TR — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$196.3M
营收增速更快
OFIX
高出0.5%
1.5%
净利率更高
TR
高出15.7%
-1.0%
自由现金流更多
TR
多$44.2M
$16.8M
两年增速更快
TR
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $196.3M |
| 净利润 | $-2.2M | $28.8M |
| 毛利率 | 71.1% | 35.7% |
| 营业利润率 | 0.2% | 17.0% |
| 净利率 | -1.0% | 14.7% |
| 营收同比 | 2.0% | 1.5% |
| 净利润同比 | 92.4% | 27.9% |
| 每股收益（稀释后） | $-0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXTR
| Q4 25 | $219.9M | $196.3M | ||
| Q3 25 | $205.6M | $232.7M | ||
| Q2 25 | $203.1M | $155.1M | ||
| Q1 25 | $193.6M | $148.5M | ||
| Q4 24 | $215.7M | $193.4M | ||
| Q3 24 | $196.6M | $225.9M | ||
| Q2 24 | $198.6M | $150.7M | ||
| Q1 24 | $188.6M | $153.2M |
净利润OFIXTR
| Q4 25 | $-2.2M | $28.8M | ||
| Q3 25 | $-22.8M | $35.7M | ||
| Q2 25 | $-14.1M | $17.5M | ||
| Q1 25 | $-53.1M | $18.1M | ||
| Q4 24 | $-29.1M | $22.5M | ||
| Q3 24 | $-27.4M | $32.8M | ||
| Q2 24 | $-33.4M | $15.6M | ||
| Q1 24 | $-36.0M | $15.8M |
毛利率OFIXTR
| Q4 25 | 71.1% | 35.7% | ||
| Q3 25 | 72.2% | 34.1% | ||
| Q2 25 | 68.7% | 36.4% | ||
| Q1 25 | 62.8% | 35.3% | ||
| Q4 24 | 69.0% | 39.1% | ||
| Q3 24 | 68.7% | 34.1% | ||
| Q2 24 | 67.8% | 33.5% | ||
| Q1 24 | 67.5% | 32.7% |
营业利润率OFIXTR
| Q4 25 | 0.2% | 17.0% | ||
| Q3 25 | -8.3% | 13.9% | ||
| Q2 25 | -7.9% | 7.8% | ||
| Q1 25 | -25.2% | 15.5% | ||
| Q4 24 | -5.3% | 20.0% | ||
| Q3 24 | -9.6% | 15.6% | ||
| Q2 24 | -12.5% | 10.2% | ||
| Q1 24 | -15.6% | 7.3% |
净利率OFIXTR
| Q4 25 | -1.0% | 14.7% | ||
| Q3 25 | -11.1% | 15.3% | ||
| Q2 25 | -6.9% | 11.3% | ||
| Q1 25 | -27.4% | 12.2% | ||
| Q4 24 | -13.5% | 11.6% | ||
| Q3 24 | -13.9% | 14.5% | ||
| Q2 24 | -16.8% | 10.4% | ||
| Q1 24 | -19.1% | 10.3% |
每股收益（稀释后）OFIXTR
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.57 | — | ||
| Q2 25 | $-0.36 | — | ||
| Q1 25 | $-1.35 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.71 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-0.95 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $176.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $941.0M |
| 总资产 | $850.6M | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXTR
| Q4 25 | $82.0M | $176.6M | ||
| Q3 25 | $62.9M | $119.8M | ||
| Q2 25 | $65.6M | $170.5M | ||
| Q1 25 | $58.0M | $176.6M | ||
| Q4 24 | $83.2M | $194.6M | ||
| Q3 24 | $30.1M | $163.2M | ||
| Q2 24 | $26.4M | $131.2M | ||
| Q1 24 | $27.0M | $159.4M |
总债务OFIXTR
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXTR
| Q4 25 | $450.0M | $941.0M | ||
| Q3 25 | $442.5M | $918.9M | ||
| Q2 25 | $458.3M | $893.1M | ||
| Q1 25 | $458.3M | $879.4M | ||
| Q4 24 | $503.1M | $870.7M | ||
| Q3 24 | $525.9M | $870.2M | ||
| Q2 24 | $546.0M | $841.4M | ||
| Q1 24 | $570.3M | $834.4M |
总资产OFIXTR
| Q4 25 | $850.6M | $1.3B | ||
| Q3 25 | $832.6M | $1.2B | ||
| Q2 25 | $837.2M | $1.2B | ||
| Q1 25 | $823.1M | $1.1B | ||
| Q4 24 | $893.3M | $1.1B | ||
| Q3 24 | $867.9M | $1.1B | ||
| Q2 24 | $882.0M | $1.1B | ||
| Q1 24 | $906.0M | $1.1B |
负债/权益比OFIXTR
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $73.3M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $61.0M |
| 自由现金流率自由现金流/营收 | 7.6% | 31.1% |
| 资本支出强度资本支出/营收 | 4.9% | 6.3% |
| 现金转化率经营现金流/净利润 | — | 2.55× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $96.4M |
8季度趋势，按日历期对齐
经营现金流OFIXTR
| Q4 25 | $27.7M | $73.3M | ||
| Q3 25 | $12.4M | $62.2M | ||
| Q2 25 | $11.6M | $-8.5M | ||
| Q1 25 | $-18.4M | $3.6M | ||
| Q4 24 | $23.7M | $68.8M | ||
| Q3 24 | $11.7M | $61.3M | ||
| Q2 24 | $9.0M | $-12.6M | ||
| Q1 24 | $-18.6M | $21.4M |
自由现金流OFIXTR
| Q4 25 | $16.8M | $61.0M | ||
| Q3 25 | $2.5M | $50.7M | ||
| Q2 25 | $4.5M | $-16.0M | ||
| Q1 25 | $-25.1M | $750.0K | ||
| Q4 24 | $15.2M | $64.7M | ||
| Q3 24 | $6.3M | $55.8M | ||
| Q2 24 | $-360.0K | $-16.6M | ||
| Q1 24 | $-29.1M | $16.9M |
自由现金流率OFIXTR
| Q4 25 | 7.6% | 31.1% | ||
| Q3 25 | 1.2% | 21.8% | ||
| Q2 25 | 2.2% | -10.3% | ||
| Q1 25 | -13.0% | 0.5% | ||
| Q4 24 | 7.0% | 33.5% | ||
| Q3 24 | 3.2% | 24.7% | ||
| Q2 24 | -0.2% | -11.0% | ||
| Q1 24 | -15.4% | 11.0% |
资本支出强度OFIXTR
| Q4 25 | 4.9% | 6.3% | ||
| Q3 25 | 4.8% | 5.0% | ||
| Q2 25 | 3.5% | 4.8% | ||
| Q1 25 | 3.5% | 1.9% | ||
| Q4 24 | 4.0% | 2.1% | ||
| Q3 24 | 2.7% | 2.4% | ||
| Q2 24 | 4.7% | 2.6% | ||
| Q1 24 | 5.6% | 2.9% |
现金转化率OFIXTR
| Q4 25 | — | 2.55× | ||
| Q3 25 | — | 1.74× | ||
| Q2 25 | — | -0.49× | ||
| Q1 25 | — | 0.20× | ||
| Q4 24 | — | 3.06× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | -0.81× | ||
| Q1 24 | — | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
TR
| Products | $194.3M | 99% |
| Rental And Royalty | $1.9M | 1% |
